Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Schultz the consultant: Former CDRH Director Daniel Schultz has joined Greenleaf Health as senior VP for medical devices and combination products, the consulting firm announced Jan. 6. Schultz left the device center in August as the new FDA leadership reassessed past CDRH device review practices, which have come under intensifying public criticism (1"The Gray Sheet" Aug. 17, 2009). He had led the center for five years and worked at CDRH for 15 years. Greenleaf is developing into a regular landing spot for recently departed top FDA officials. Taryn Fritz Warpole, former deputy chief of staff, joined the firm in July and former Commissioner Andrew von Eschenbach signed on as a senior advisor in March (2"The Gray Sheet" March 9, 2009). Former FDA Chief of Staff Patrick Ronan founded the consulting practice

You may also be interested in...



It's Official: Jeffrey Shuren Is New Device Center Director

FDA and Jeffrey Shuren have made it official: the neurologist, lawyer and experienced FDA staffer was named director of the agency's Center for Devices and Radiological Health Jan. 20

It's Official: Jeffrey Shuren Is New Device Center Director

FDA and Jeffrey Shuren have made it official: the neurologist, lawyer and experienced FDA staffer was named director of the agency's Center for Devices and Radiological Health Jan. 20

People In Brief

Bayer and Thermo CEOs: Thermo Fisher Scientific CEO Marijn E. Dekkers has resigned to take the CEO post of pharmaceutical giant and glucose monitor maker Bayer. Dekkers will not take the helm of Bayer until Oct. 1, 2010, when current CEO Werner Wenning retires. But laboratory equipment manufacturer Thermo announced that its Chief Operating Officer Marc N. Casper will be promoted to CEO next month. Dekkers will join Bayer's board in January and will transitionally become CEO of Bayer's health care unit, which houses the firm's drug and diabetes products, when Bayer HealthCare CEO Arthur J. Higgins leaves the company in the first half of 2010. Bayer also announced that its chief financial officer, Klaus Kühn, will retire next April

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT028361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel